サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：微小残存病変 (MRD) 検査の世界市場 (2019-2029年)：検査タイプ・技術・用途・エンドユーザー・地域別の市場規模・シェア・動向分析・機会・予測
市場調査レポート
商品コード
1274820

微小残存病変 (MRD) 検査の世界市場 (2019-2029年)：検査タイプ・技術・用途・エンドユーザー・地域別の市場規模・シェア・動向分析・機会・予測

Minimal Residual Disease Testing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Test Type ; By Technology ; By Application ; By End Use ; By Region
出版日: | 発行: Blueweave Consulting | ページ情報: 英文 400 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
微小残存病変 (MRD) 検査の世界市場 (2019-2029年)：検査タイプ・技術・用途・エンドユーザー・地域別の市場規模・シェア・動向分析・機会・予測
出版日: 2023年05月05日
発行: Blueweave Consulting
ページ情報: 英文 400 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の微小残存病変 (MRD) 検査の市場規模は、2022年の15億4,000万米ドルから、予測期間中は14.6％のCAGRで推移し、2029年には39億6,000万米ドルの規模に成長すると予測されています。

世界の微小残存病変 (MRD) 検査の市場は、精密医療アプローチの高い採用率、癌の早期診断・発見へのトレンドの高まり、世界的な癌有病率の増加により、正確で信頼性の高い診断検査への需要が急増していることから活況を呈しています。

当レポートでは、世界の微小残存病変 (MRD) 検査の市場を調査し、市場概要、市場成長への各種影響因子の分析、技術動向、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査の枠組み

第2章 エグゼクティブサマリー

第3章 世界の微小残存病変 (MRD) 検査市場に関する洞察

  • 産業のバリューチェーン分析
  • DROC分析
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 技術の進歩/最近の開発
  • 規制の枠組み
  • ポーターのファイブフォース分析

第4章 世界の微小残存病変 (MRD) 検査市場：概要

  • 市場規模・予測
  • 市場シェア・予測
  • 検査タイプ別
    • DNAベース検査
    • RNAベース検査
    • 免疫学的検査
    • その他
  • 技術別
    • NGS・PCR
    • フローサイトメトリー
    • 蛍光In-Situハイブリダイゼーション
    • その他
  • 用途別
    • 血液悪性腫瘍
    • 固形腫瘍
    • その他
  • エンドユーザー別
    • 病院
    • 専門クリニック
    • 診断ラボ
    • 研究・学術機関
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ

第5章 北米の微小残存病変 (MRD) 検査市場

  • 市場規模・予測
  • 市場シェア・予測
    • 検査タイプ別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別

第6章 欧州の微小残存病変 (MRD) 検査市場

  • 市場規模・予測
  • 市場シェア・予測
    • 検査タイプ別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別

第7章 アジア太平洋の微小残存病変 (MRD) 検査市場

  • 市場規模・予測
  • 市場シェア・予測
    • 検査タイプ別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別

第8章 ラテンアメリカの微小残存病変 (MRD) 検査市場

  • 市場規模・予測
  • 市場シェア・予測
    • 検査タイプ別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別

第9章 中東・アフリカの微小残存病変 (MRD) 検査市場

  • 市場規模・予測
  • 市場シェア・予測
    • 検査タイプ別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別

第10章 競合情勢

  • 主要企業・製品リスト
  • 市場シェア分析
  • 競合ベンチマーキング：経営パラメーター別
  • 主要な戦略的展開 (M&A・提携など)

第11章 世界の微小残存病変 (MRD) 検査市場に対するCOVID-19の影響

第12章 企業プロファイル (企業概要・財務マトリックス・競合情勢・主要人材・主な競合相手・連絡先・戦略的展望・SWOT分析)

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Agilent Technologies
  • ARUP Laboratories
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Janssen Diagnostics LLC
  • Luminex Corporation
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • QIAGEN N.V.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
  • その他の主要企業

第13章 主な戦略的提言

第14章 調査手法

目次
Product Code: BWC23357

Global Minimal Residual Disease Testing Market Size More Than Doubles to Reach USD 4 Billion by 2029.

Global minimal residual disease testing market is flourishing because of high adoption of precision medicine approaches, growing trend towards early cancer diagnosis and detection, and increasing prevalence of cancer worldwide, leading to surging demand for accurate and reliable diagnostic tests.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global minimal residual disease testing market size at USD 1.54 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global minimal residual disease testing market size to grow at a significant CAGR of 14.6% reaching a value of USD 3.96 billion by 2029. Major growth drivers for global minimal residual disease testing market include growing cancer patient population, awareness among consumers of the importance of therapy, as well as increased investments in research, and high disposable income in developing nations. A primary growth driver of the market growth is the escalating prevalence of cancer. According to the World Health Organization, cancer is currently the second most common cause of death worldwide. In 2020, there were 19.3 million reported cases of cancer and 9.96 million deaths related to the disease. The International Agency for Research on Cancer predicts that the number of cancer cases will rise to 21.9 million by 2025 and 24.6 million by 2030. As a result, governments are expected to establish new cancer screening programs to address this surge in cases. Also, the market is expected to experience growth due to increased investments in MRD (minimal residual disease) testing programs. MRD diagnostic and monitoring research is expanding, which is creating demand for these services. However, limited availability of skilled healthcare professionals to perform and interpret MRD tests and concerns over the accuracy and reliability of MRD tests are anticipated to restrain the overall market growth.

Global Minimal Residual Disease Testing Market - Overview:

Global minimal residual disease (MRD) testing market refers to the market for diagnostic tests used to detect the presence of cancer cells in patients who have undergone treatment. MRD testing is a highly sensitive and specific technique that is capable of detecting small amounts of cancer cells that may remain in a patient's body after treatment. The MRD testing market includes products and services such as assays, flow cytometers, and other testing equipment, as well as related services like sample preparation and analysis. The market caters to healthcare providers, research organizations, and pharmaceutical companies who use MRD testing for disease monitoring, treatment selection, and clinical trial endpoints.

Impact of COVID-19 on Global Minimal Residual Disease Testing Market

COVID-19 had a detrimental impact on the global minimal residual disease (MRD) testing market. With the focus on the virus and the strain on healthcare systems, the demand for MRD testing was affected. The restrictions imposed due to the pandemic, such as social distancing and lockdown measures, have also resulted in delays or cancellations of elective procedures, including MRD testing. Also, the disruption in the supply chain and manufacturing processes has led to a shortage of necessary components and instruments required for testing. The uncertain economic conditions and reduced funding for research and development may further impede the growth of the MRD testing market in the near future.

Global Minimal Residual Disease Testing Market - By Test Type

Based on test type, the global minimal residual disease testing market is divided into DNA-Based Test, RNA-Based Test, and Immunological Test segments. The DNA-based tests segment held the highest share of the MRD testing market due to their high sensitivity and specificity in detecting cancer cells. However, the RNA-based tests segment is expected to grow at the highest CAGR during the forecast period due to advancements in technologies like next-generation sequencing (NGS) and digital PCR.

Competitive Landscape:

Major players operating in the global minimal residual disease testing market include: Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, ARUP Laboratories, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Illumina, Inc., Invivoscribe, Inc., Janssen Diagnostics LLC, Luminex Corporation, Myriad Genetics, Inc., Natera, Inc., QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Minimal Residual Disease Testing Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Minimal Residual Disease Testing Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Minimal Residual Disease Testing Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Growing prevalence of cancer worldwide, leading to increased demand for accurate and reliable diagnostic tests
      • 3.2.1.2. Increasing adoption of precision medicine approaches
      • 3.2.1.3. Growing trend towards early cancer diagnosis and detection
    • 3.2.2. Restraints
      • 3.2.2.1. Limited availability of skilled healthcare professionals to perform and interpret MRD tests
      • 3.2.2.2. Concerns over the accuracy and reliability of MRD tests
    • 3.2.3. Opportunities
      • 3.2.3.1. Increasing adoption of advanced technologies, such as next-generation sequencing
      • 3.2.3.2. Growing trend towards personalized cancer care, which requires accurate and reliable measurement
    • 3.2.4. Challenges
      • 3.2.4.1. Need for continuous investment in research and development to stay competitive
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Minimal Residual Disease Testing Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Test Type
      • 4.2.1.1. DNA-Based Test
      • 4.2.1.2. RNA-Based Test
      • 4.2.1.3. Immunological Test
      • 4.2.1.4. Others
    • 4.2.2. By Technology
      • 4.2.2.1. NGS, PCR
      • 4.2.2.2. Flow Cytometry
      • 4.2.2.3. Fluorescence In-Situ Hybridization
      • 4.2.2.4. Others
    • 4.2.3. By Application
      • 4.2.3.1. Hematological Malignancies
      • 4.2.3.2. Solid Tumors
      • 4.2.3.3. Others
    • 4.2.4. By End Use
      • 4.2.4.1. Hospitals
      • 4.2.4.2. Specialty Clinics
      • 4.2.4.3. Diagnostic Laboratories
      • 4.2.4.4. Research and Academic Institutes
      • 4.2.4.5. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific (APAC)
      • 4.2.5.4. Latin America (LATAM)
      • 4.2.5.5. Middle East and Africa (MEA)

5. North America Minimal Residual Disease Testing Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type
    • 5.2.2. By Technology
    • 5.2.3. By Application
    • 5.2.4. By End Use
    • 5.2.5. By Country
      • 5.2.5.1. United States
      • 5.2.5.1.1. By Test Type
      • 5.2.5.1.2. By Technology
      • 5.2.5.1.3. By Application
      • 5.2.5.1.4. By End Use
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Test Type
      • 5.2.5.2.2. By Technology
      • 5.2.5.2.3. By Application
      • 5.2.5.2.4. By End Use

6. Europe Minimal Residual Disease Testing Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End Use
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Test Type
      • 6.2.5.1.2. By Technology
      • 6.2.5.1.3. By Application
      • 6.2.5.1.4. By End Use
      • 6.2.5.2. United Kingdom
      • 6.2.5.2.1. By Test Type
      • 6.2.5.2.2. By Technology
      • 6.2.5.2.3. By Application
      • 6.2.5.2.4. By End Use
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Test Type
      • 6.2.5.3.2. By Technology
      • 6.2.5.3.3. By Application
      • 6.2.5.3.4. By End Use
      • 6.2.5.4. France
      • 6.2.5.4.1. By Test Type
      • 6.2.5.4.2. By Technology
      • 6.2.5.4.3. By Application
      • 6.2.5.4.4. By End Use
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Test Type
      • 6.2.5.5.2. By Technology
      • 6.2.5.5.3. By Application
      • 6.2.5.5.4. By End Use
      • 6.2.5.6. Belgium
      • 6.2.5.6.1. By Test Type
      • 6.2.5.6.2. By Technology
      • 6.2.5.6.3. By Application
      • 6.2.5.6.4. By End Use
      • 6.2.5.7. Russia
      • 6.2.5.7.1. By Test Type
      • 6.2.5.7.2. By Technology
      • 6.2.5.7.3. By Application
      • 6.2.5.7.4. By End Use
      • 6.2.5.8. The Netherlands
      • 6.2.5.8.1. By Test Type
      • 6.2.5.8.2. By Technology
      • 6.2.5.8.3. By Application
      • 6.2.5.8.4. By End Use
      • 6.2.5.9. Rest of Europe
      • 6.2.5.9.1. By Test Type
      • 6.2.5.9.2. By Technology
      • 6.2.5.9.3. By Application
      • 6.2.5.9.4. By End Use

7. Asia-Pacific Minimal Residual Disease Testing Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End Use
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Test Type
      • 7.2.5.1.2. By Technology
      • 7.2.5.1.3. By Application
      • 7.2.5.1.4. By End Use
      • 7.2.5.2. India
      • 7.2.5.2.1. By Test Type
      • 7.2.5.2.2. By Technology
      • 7.2.5.2.3. By Application
      • 7.2.5.2.4. By End Use
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Test Type
      • 7.2.5.3.2. By Technology
      • 7.2.5.3.3. By Application
      • 7.2.5.3.4. By End Use
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Test Type
      • 7.2.5.4.2. By Technology
      • 7.2.5.4.3. By Application
      • 7.2.5.4.4. By End Use
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Test Type
      • 7.2.5.5.2. By Technology
      • 7.2.5.5.3. By Application
      • 7.2.5.5.4. By End Use
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Test Type
      • 7.2.5.6.2. By Technology
      • 7.2.5.6.3. By Application
      • 7.2.5.6.4. By End Use
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Test Type
      • 7.2.5.7.2. By Technology
      • 7.2.5.7.3. By Application
      • 7.2.5.7.4. By End Use
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Test Type
      • 7.2.5.8.2. By Technology
      • 7.2.5.8.3. By Application
      • 7.2.5.8.4. By End Use
      • 7.2.5.9. Vietnam
      • 7.2.5.9.1. By Test Type
      • 7.2.5.9.2. By Technology
      • 7.2.5.9.3. By Application
      • 7.2.5.9.4. By End Use
      • 7.2.5.10. Rest of APAC
      • 7.2.5.10.1. By Test Type
      • 7.2.5.10.2. By Technology
      • 7.2.5.10.3. By Application
      • 7.2.5.10.4. By End Use

8. Latin America Minimal Residual Disease Testing Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End Use
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Test Type
      • 8.2.5.1.2. By Technology
      • 8.2.5.1.3. By Application
      • 8.2.5.1.4. By End Use
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Test Type
      • 8.2.5.2.2. By Technology
      • 8.2.5.2.3. By Application
      • 8.2.5.2.4. By End Use
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Test Type
      • 8.2.5.3.2. By Technology
      • 8.2.5.3.3. By Application
      • 8.2.5.3.4. By End Use
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Test Type
      • 8.2.5.4.2. By Technology
      • 8.2.5.4.3. By Application
      • 8.2.5.4.4. By End Use
      • 8.2.5.5. Rest of LATAM
      • 8.2.5.5.1. By Test Type
      • 8.2.5.5.2. By Technology
      • 8.2.5.5.3. By Application
      • 8.2.5.5.4. By End Use

9. Middle East & Africa Minimal Residual Disease Testing Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End Use
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Test Type
      • 9.2.5.1.2. By Technology
      • 9.2.5.1.3. By Application
      • 9.2.5.1.4. By End Use
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Test Type
      • 9.2.5.2.2. By Technology
      • 9.2.5.2.3. By Application
      • 9.2.5.2.4. By End Use
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Test Type
      • 9.2.5.3.2. By Technology
      • 9.2.5.3.3. By Application
      • 9.2.5.3.4. By End Use
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Test Type
      • 9.2.5.4.2. By Technology
      • 9.2.5.4.3. By Application
      • 9.2.5.4.4. By End Use
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Test Type
      • 9.2.5.5.2. By Technology
      • 9.2.5.5.3. By Application
      • 9.2.5.5.4. By End Use
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Test Type
      • 9.2.5.6.2. By Technology
      • 9.2.5.6.3. By Application
      • 9.2.5.6.4. By End Use
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Test Type
      • 9.2.5.7.2. By Technology
      • 9.2.5.7.3. By Application
      • 9.2.5.7.4. By End Use
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Test Type
      • 9.2.5.8.2. By Technology
      • 9.2.5.8.3. By Application
      • 9.2.5.8.4. By End Use

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Minimal Residual Disease Testing Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Minimal Residual Disease Testing Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Abbott Laboratories
  • 12.2. Adaptive Biotechnologies
  • 12.3. Agilent Technologies
  • 12.4. ARUP Laboratories
  • 12.5. Bio-Rad Laboratories
  • 12.6. F. Hoffmann-La Roche AG
  • 12.7. Illumina, Inc.
  • 12.8. Invivoscribe, Inc.
  • 12.9. Janssen Diagnostics LLC
  • 12.10. Luminex Corporation
  • 12.11. Myriad Genetics, Inc.
  • 12.12. Natera, Inc.
  • 12.13. QIAGEN N.V.
  • 12.14. Sysmex Corporation
  • 12.15. Thermo Fisher Scientific, Inc.
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations